The Belgian immunotherapy company iTeos Therapeutics SA has appointed Matthew Call as chief operating officer to guide business development as its cancer drugs progress through the clinic. iTeos’ lead programme is an adenosine A2A receptor antagonist in Phase 1 for advanced cancer. Mr Call was previously COO at Endocyte Inc, a US cancer company that was acquired by Novartis in December 2018. He received a Master of Business Administration degree from the Purdue University Krannert School of Management in the US.
iTeos Therapeutics announced the appointment on 13 August 2019.
Copyright 2019 Evernow Publishing Ltd